Our findings revealed a novel mechanism in which the reduction in Cdc42 regulated by dopamine D2R contributes to the pathophysiology of parkinsonian mice, indicating that Cdc42 is an effective target for treating PD. This evidence concerns the gene CDC42 and Parkinson disease.